Advertisement


Matthew J. Ellis, PhD, MB, BCh, on Breast Cancer: Results of the FALCON Trial

2016 ESMO Congress

Advertisement

Matthew J. Ellis, PhD, MB, BCh, of the Baylor College of Medicine, discusses phase III study findings on fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced disease. (Abstract LBA14)



Related Videos

Breast Cancer

Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial

Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)

Bladder Cancer

Arjun V. Balar, MD, on Urothelial Cancer: Results From KEYNOTE-052

Arjun V. Balar, MD, of the NYU Perlmutter Cancer Center, discusses preliminary phase II study findings on pembrolizumab as first-line therapy for advanced/unresectable or metastatic urothelial cancer. (Abstract LBA32)

Skin Cancer

Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial (German Language Version)

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses in German study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Cancer: Results From the CheckMate 275 Trial

Sumanta K. Pal, MD, of the City of Hope, discusses phase II findings on the efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer who have received prior treatment. Follow him on Twitter: @montypal

Advertisement

Advertisement




Advertisement